<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="rmv2163-tbl-0001" xml:lang="en" content-type="TABLE" orientation="portrait" position="float">
 <label>TABLE 1</label>
 <caption>
  <p>Viral infections in which azithromycin has demonstrated anti‐viral effects</p>
 </caption>
 <table frame="hsides" rules="all">
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <thead valign="bottom">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="bottom" rowspan="1" colspan="1">Pathogen</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Findings</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Method</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Study</th>
   </tr>
  </thead>
  <tbody valign="top">
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Human rhinovirus (Picornavirus)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Enhanced viral‐induced type I and III IFN leading to reduced RV replication and release</td>
    <td align="left" valign="top" rowspan="1" colspan="1">In vitro study. PBEC. 10 μM, 50 μM</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Gielen et al
     <xref rid="rmv2163-bib-0007" ref-type="ref">
      <sup>7</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
    <td align="left" valign="top" rowspan="1" colspan="1">Reduced RV replication</td>
    <td align="left" valign="top" rowspan="1" colspan="1">In vitro study. PBEC from cystic fibrosis patients. 50 μM</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Schogler et al
     <xref rid="rmv2163-bib-0008" ref-type="ref">
      <sup>8</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
    <td align="left" valign="top" rowspan="1" colspan="1">In vitro study. PBECs and BEAS‐2B cells 50 μM, 10 μM</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Porter et al
     <xref rid="rmv2163-bib-0009" ref-type="ref">
      <sup>9</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
    <td align="left" valign="top" rowspan="1" colspan="1">Increases RV PRR presentation</td>
    <td align="left" valign="top" rowspan="1" colspan="1">In vitro study. PBEC. 10 μM, 50 μM</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Gielen et al
     <xref rid="rmv2163-bib-0007" ref-type="ref">
      <sup>7</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
    <td align="left" valign="top" rowspan="1" colspan="1">Induces anti‐viral ISGs viperin and MxA</td>
    <td align="left" valign="top" rowspan="1" colspan="1">In vitro study. PBECs and BEAS‐2B cells 50 μM, 10 μM</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Porter et al
     <xref rid="rmv2163-bib-0009" ref-type="ref">
      <sup>9</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Coronaviruses (alpha and beta)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">AZM associated with reduced viral load in children with coronaviruses</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Clinical trial. Dose ≥20 mg/kg</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Doan et al
     <xref rid="rmv2163-bib-0010" ref-type="ref">
      <sup>10</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Zika (Flavivirus)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">AZM markedly reduces viral proliferation and virus‐induced cytopathic effects</td>
    <td align="left" valign="top" rowspan="1" colspan="1">In vitro study. U87 glial cells and hPSC‐derived astrocytes, 0 μM to &gt;100 μM</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Retallack et al
     <xref rid="rmv2163-bib-0011" ref-type="ref">
      <sup>11</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
    <td align="left" valign="top" rowspan="1" colspan="1">AZM upregulates type I and III interferon responses</td>
    <td align="left" valign="top" rowspan="1" colspan="1">In vitro study. HT‐29 human colon epithelial cell line and A549 lung epithelial cell line. 10 μM, 50 μM</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Li et al
     <xref rid="rmv2163-bib-0012" ref-type="ref">
      <sup>12</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
    <td align="left" valign="top" rowspan="1" colspan="1">AZM upregulates viral pathogen recognition receptors MDA5 and RIG‐1</td>
    <td align="left" valign="top" rowspan="1" colspan="1">In vitro study. A549 lung epithelial cell line. 10 μM, 50 μM</td>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
    <td align="left" valign="top" rowspan="1" colspan="1">AZM increases levels of phosphorylated TBK1 and IRF3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">In vitro study. HT‐29 human colon epithelial cell line, 10 μM, 50 μM</td>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
    <td align="left" valign="top" rowspan="1" colspan="1">Human primary fibroblasts, 5 μM, 20 μM. RAW264.7 macrophage cells 1.5 μM, 3 μM</td>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Enteroviruses (Picornaviruses)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">AZM improved survival and clinical symptom scores in murine model</td>
    <td align="left" valign="top" rowspan="1" colspan="1">In vivo study. Mice infected i.p. with EV‐A71‐MZ‐MA1. AZM dose 30 mg/kg/day</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Zeng et al
     <xref rid="rmv2163-bib-0013" ref-type="ref">
      <sup>13</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Ebola (Ebola viruses)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">AZM demonstrates high in vitro anti‐viral potency and low cytotoxicity</td>
    <td align="left" valign="top" rowspan="1" colspan="1">In vitro study. HeLa cells (viral replication). HEK 293T cells (viral entry and cytotoxicity). 0.5 to 50 μM</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Madrid et al
     <xref rid="rmv2163-bib-0014" ref-type="ref">
      <sup>14</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">SARS (Coronavirus)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">AZM associated with improvement in 90 d survival rate and time to discontinuation of mechanical ventilation</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Single‐centre, retrospective cohort evaluation of hospitalized patients with moderate or severe ARDS, using a propensity score analysis</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Kawamura et al
     <xref rid="rmv2163-bib-0015" ref-type="ref">
      <sup>15</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Influenza A (Orthomyxovirus)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Reduction in IL‐6, IL‐8, IL‐17, CXCL9, sTNF and CRP</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Randomised, open‐label, multicentre trial of patients with severe influenza. 500 mg AZM od + 75 mg oseltamivir bd/75 mg oseltamivir bd.</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Lee et al
     <xref rid="rmv2163-bib-0016" ref-type="ref">
      <sup>16</sup>
     </xref>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot id="rmv2163-ntgp-0001">
  <fn id="rmv2163-note-0001">
   <p>Abbreviations: AZM, azithromycin; CRP, C‐reactive protein; CXCL, C‐X‐C motif ligand; hPSC, human pluripotent stem cell; IL, interleukin; IFN, interferon; IRF3, Interferon Regulatory Factor 3; ISG, interferon‐stimulated gene; MDA5, melanoma differentiation‐associated protein 5; MxA, myxoma virus resistance A; PBEC, primary bronchial epithelial cell; PRR, pattern recognition receptor; RIG‐1, retinoic acid‐inducible gene 1, RV, rhinovirus; SARS, severe acute respiratory syndrome; TBK1, TANK‐binding kinase 1.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
